Prospective Biobanking Study in Cancer Patients Aiming at Better Understand the Link Between the Molecular Alterations of the Tumor Itself, Its Microenvironment and Immune Response (SCANDARE) (SCANDARE)
Sponsor: Institut Curie
Listed as NCT03017573, this NA trial focuses on Cervical Cancer and Head and Neck Cancer and remains actively recruiting participants. Sponsored by Institut Curie, it has been updated 14 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
14 versions recorded-
Feb 2026 — Present [monthly]
Recruiting NA
-
Jan 2026 — Feb 2026 [monthly]
Recruiting NA
-
Sep 2025 — Jan 2026 [monthly]
Recruiting NA
-
May 2025 — Sep 2025 [monthly]
Recruiting NA
-
Sep 2024 — May 2025 [monthly]
Recruiting NA
▶ Show 9 earlier versions
-
Jul 2024 — Sep 2024 [monthly]
Recruiting NA
-
May 2024 — Jul 2024 [monthly]
Recruiting NA
-
Feb 2024 — May 2024 [monthly]
Recruiting NA
-
Jun 2023 — Feb 2024 [monthly]
Recruiting NA
-
Jan 2022 — Jun 2023 [monthly]
Recruiting NA
-
Jan 2021 — Jan 2022 [monthly]
Recruiting NA
-
Nov 2018 — Jan 2021 [monthly]
Recruiting NA
-
Jun 2018 — Nov 2018 [monthly]
Recruiting NA
-
Feb 2017 — Jun 2018 [monthly]
Recruiting NA
First recorded
Jan 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Institut Curie
For direct contact, visit the study record on ClinicalTrials.gov .